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Abstract
Activated leukocyte cell adhesion molecule (ALCAM, CD166) is expressed in various tissues, cancers, and cancer-initiating
cells. Alterations in expression of ALCAM have been reported in several human tumors, and cell adhesion functions have
been proposed to explain its association with cancer. Here we documented high levels of ALCAM expression in human
thyroid tumors and cell lines. Through proteomic characterization of ALCAM expression in the human papillary thyroid
carcinoma cell line TPC-1, we identified the presence of a full-length membrane-associated isoform in cell lysate and of
soluble ALCAM isoforms in conditioned medium. This finding is consistent with proteolytically shed ALCAM ectodomains.
Nonspecific agents, such as phorbol myristate acetate (PMA) or ionomycin, provoked increased ectodomain shedding.
Epidermal growth factor receptor stimulation also enhanced ALCAM secretion through an ADAM17/TACE-dependent
pathway. ADAM17/TACE was expressed in the TPC-1 cell line, and ADAM17/TACE silencing by specific small interfering RNAs
reduced ALCAM shedding. In addition, the CGS27023A inhibitor of ADAM17/TACE function reduced ALCAM release in a
dose-dependent manner and inhibited cell migration in a wound-healing assay. We also provide evidence for the existence
of novel O-glycosylated forms and of a novel 60-kDa soluble form of ALCAM, which is particularly abundant following cell
stimulation by PMA. ALCAM expression in papillary and medullary thyroid cancer specimens and in the surrounding non-
tumoral component was studied by western blot and immunohistochemistry, with results demonstrating that tumor cells
overexpress ALCAM. These findings strongly suggest the possibility that ALCAM may have an important role in thyroid
tumor biology.
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Introduction
Thyroid tumours are the most frequent malignancies of the
endocrine system [1]. The most common type is papillary thyroid
carcinoma (PTC), a well-differentiated tumor arising in follicular cells
that accounts for 80–90% of all thyroid malignancies. Medullary
thyroid cancer (MTC) accounts for 5 to 10 percent of thyroid cancer
cases and arises from calcitonin-producing C cells [2].
The epithelial to mesenchymal transition (EMT) is an essential
step for invasiveness and progression in these tumors [3;4]. Crucial
to this transition is the downregulation of cell–cell contacts, most
notably E-cadherin–based adhesion [5]. Indeed, adhesion path-
ways and their altered regulation by B-catenin and Wnt signaling
are important in the progression of thyroid tumors [6].
Among cell adhesion molecules, the neuron–glia-related cell-
adhesion molecule (NrCAM) has been shown to be involved in
thyroid carcinogenesis [7–9]. The loss of neural cell adhesion
molecule CD56/NCAM expression is significant in papillary
carcinoma (up to 100%), and such loss can serve as a specific and
sensitive marker of PTC [10;11]. This gradual change seems to
parallel a decrease in nuclear expression of thyroid transcription
factor (TTF-1), an epithelial-specific transcription factor which
regulates the changes in gene expression patterns that underlie
EMT [12].
This report focuses on the activated leukocyte cell adhesion
molecule (ALCAM or CD166), a member of the immunoglobulin
superfamily, [13] in papillary and medullary thyroid tumors.
Altered expression of ALCAM has been associated with
differentiation state and progression in many tumors [14–21]. In
addition, ALCAM is a marker of cancer stem cells and its
expression at the tumor cell surface has been correlated with
shortened survival in colon-rectal cancers [17;22] and with the
vertical growth phase of progression in cutaneous melanoma [23].
On the contrary, in breast [24–26] and ovarian cancer [20]
ALCAM cytoplasmic overexpression and low membrane expres-
sion were associated with disease progression. Therefore ALCAM
at the cell surface plays a divergent role in the progression of
different tumor types. Very recent data indicate that both
transfection of mimics of microRNA-192 or -215 or ALCAM-
specific siRNA significantly inhibit ALCAM expression and
increase migration in a cell line model of gastric cancer [27].
Collectively these data suggest that the ALCAM relocalization
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the migratory properties of malignant cells facilitating metastatic
dissemination in several cancers.
In this context, we have previously demonstrated that ALCAM
is released from epithelial ovarian cancer (EOC) cells by a
metalloprotease-dependent mechanism, leading to the generation
of a natural soluble form of ALCAM that contains the greater part
of the ectodomain. We have also shown that ALCAM shedding
from the EOC can be enhanced by stimuli such as pervanadate
(PV), phorbol myristate acetate (PMA), and epidermal growth
factor (EGF) and can be blocked by inhibitors of ADAMs and by
ADAM17/TACE silencing [28]. The clinical relationship of
membrane ALCAM loss with progression in ovarian and breast
cancer may also relate to the process of ALCAM shedding by
ADAM17/TACE. Indeed, ADAM17/TACE inhibitors reduced
ovarian carcinoma cell motility in vitro [28]. In addition, shedding
of ALCAM results in the increase of sALCAM in the serum of
ovarian [28] and breast cancer patients [21], suggesting a potential
role of sALCAM as tumor biomarker, although lower levels are
also present in the plasma of healthy individuals [29]. Besides
enzymatic shedding, a recent report indicates that DNA-
methylation of ALCAM promoter might also be involved in
surface ALCAM down-regulation and breast cancer metastases
development [24].
In view of the role of ALCAM dynamics in some human
tumors, we studied its expression in thyroid tumors, which had not
been previously explored. We also specifically investigated whether
ADAM17/TACE was responsible for shedding of ALCAM in
thyroid cancer cells and we found the existence of a novel 60-kDa
soluble form of ALCAM. Finally, we studied the regulation of
ADAM17/TACE activity by PMA and EGF stimulation, and the
effects of ADAM17/TACE blockade in migration and invasion.
Results
TPC-1 cell line expresses ALCAM isoforms
Western blot analysis revealed the expression pattern of
ALCAM in total cell lysate and in conditioned medium of the
TPC-1 cell line (Fig. 1A). A single band of 105 kDa, corresponding
to the fully glycosylated isoform in the cell lysate and two distinct
isoforms of 96 and 60 kDa, respectively, were detected in
conditioned medium. These results were consistent with those
obtained with the SKOV-3 cell line known to express high levels
of ALCAM (Fig. 1A). We then hypothesized that the 96-kDa
isoform could correspond to a natural soluble form of ALCAM,
which contains the greater part of the ectodomain, [28] while the
60-kDa isoform could correspond to a new isoform resulting from
an alternative cleavage or differential glycosylation.
The glycosylation patterns of the ALCAM isoforms in cell
lysates and conditioned medium were characterized by treatment
with a mixture of endo-O-glycosidase and sialidase in the absence
(Fig. 1B) or presence of PNGaseF (Fig. 1C), followed by western
Figure 1. Western blot analysis of ALCAM expression in lysate and conditioned medium of TPC-1 cell line. (A) Analysis of TPC-1 cell
lysate (Lys) and conditioned medium (CM) using anti-ALCAM antibody. Arrow indicates membrane-localized ALCAM isoform in lysate, and
arrowheads indicate shed-ALCAM isoforms in CM, respectively. The SKOV-3 cell line was used as positive control. (B) TPC-1 cell lysate and CM were
treated or not with a mixture of O-glycosidase (O) and sialidase (S) and analyzed by western blot using anti-ALCAM antibody. Continuous arrows
indicate membrane and shed ALCAM forms before digestion, and dashed arrows indicate digestion products. (*) indicates less evident bands of
ALCAM in CM. (C) TPC-1 cell lysate and CM were treated or not with O-glycosidase (O), sialidase (S), or PNGaseF (F) and analyzed by western blot
using anti-ALCAM antibodies. Continuous arrows indicate membrane and shed ALCAM forms before digestion, and dashed arrows indicate digestion
products.
doi:10.1371/journal.pone.0017141.g001
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O-glycosidase and sialidase reduced the apparent molecular
weight of bands by,5 kDa in both cell lysate and conditioned
medium samples. The additive treatment with PNGaseF (Fig. 1C),
removing N-linked glycosyl groups, generated in the lysate sample
an ALCAM isoform corresponding to the full-length protein of
63 kDa, while in the conditioned medium two sALCAM isoform
of ,55 and 35 kDa were observed. This finding suggests that 96
and 60 kDa isoforms detected in conditioned medium result from
alternative cleavages and related glycosylation patterns.
Release of ALCAM is inducible by ionomycin and PMA
Protein shedding can be stimulated by calcium ionophores as
ionomycin, [30] or by APMA (4-aminophenylmercuric acetate)
[31] or PMA [28]. To investigate the regulation of ALCAM
shedding, we treated the TPC-1 cell line with ionomycin and
PMA. Treatment with either ionomycin or PMA increased the
total level of soluble ALCAM isoforms (Fig. 2). Intriguingly, the
treatment with PMA increased the expression of the 60-kDa
ALCAM isoform, suggesting that this previously undescribed
soluble form is produced by an alternative and inducible shedding
of the 105-kDa ALCAM isoform.
Release of ALCAM is sensitive to ADAM17/TACE
inhibition
We have previously demonstrated that EOC cells constitutively
release ALCAM, and that cell treatment with EGF enhances this
process, while ADAM17/TACE silencing inhibits it [28]. We then
tested the effects of ADAM17/TACE inhibition and activation on
ALCAM release in TPC-1 cells. TPC-1 cells indeed expressed
ADAM17/TACE (Fig. 3A) and transfection of a specific siRNA
targeting ADAM17/TACE significantly inhibited ADAM17/
TACE protein expression (Fig. 3B) and sALCAM release (49%
inhibition, Fig. 3C). We further determined whether epidermal
growth factor receptor (EGFR) activation influenced sALCAM
release via ADAM17/TACE in TPC-1 cells. To this end, cells
were treated with PV or EGF in the presence of CGS (IC50=
15969 nmol/L on recombinant ADAM17/TACE in vitro, unpub-
lished data) or solvent (DMSO). EGF increased ALCAM secretion
by about 2-fold above spontaneous release at 24 h. Cell
stimulation with PV also increased ALCAM release by two-fold
within 60 min. In a dose-dependent manner, CGS inhibited
ALCAM release induced by both stimuli and also by constitutive
shedding (Fig. 3D), suggesting a role for ADAM17/TACE in
ALCAM shedding in TPC-1 cells.
ADAM17/TACE involvement in TPC-1 cell motility
We also examined TPC-1 cell motility using the scratch assay in
presence of the ADAM17/TACE inhibitor CGS.
The analysis revealed that the distance covered by migrating
cells was significantly decreased when TPC-1 cells were exposed to
the CGS compared to cells exposed to the vehicle (DMSO) (Fig. 4).
This result indicates a correlation between TPC-1 motile behavior
and ADAM17/TACE activity.
Since the recombinant anti-ALCAM antibody I/F8 increased
EOC cells motility in a scratch assay by altering ALCAM adhesive
functions [28], we examined its activity on the TPC-1 cell line.
However, the use of I/F8 antibody failed to inhibit adhesion to the
substrate and migration through an 8 mm pore diameter
membrane and motility in the scratch assay (data not shown).
The possible reason for the efficacy of ADAM17/TACE inhibitors
and for the lack of effect of ALCAM antibody blockade may relate
to the ability of ADAM17/TACE to cleave, besides ALCAM,
several membrane substrates, including other adhesion molecules
of the CAM family [32], which may play a redundant role in
TPC-1 cell adhesion and motility.
ALCAM expression in normal and neoplastic thyroid
tissues
Western blot analysis indicated a high expression of ALCAM in
the TT and MZ-CRC1 cell lines (Fig. 5). We further explored its
expression in archival tissue samples from 11 PTCs, 5 MTCs, and
5 normal thyroids (CTRLs). As shown in Fig. 6A, the ALCAM
staining pattern appeared to be stronger in tumor samples,
especially in MTCs, and revealed several discrete bands ranging
from 120 to 100 kDa, probably due to a different level of
glycosylation. In particular, in normal thyroid tissues, ALCAM
staining was weaker and associated with a protein of ,100 kDa.
To better clarify the nature of the ALCAM isoforms, we
performed a deglycosylation of the lysates of three TPCs, two
MTCs, and three normal thyroids with PNGaseF, removing N-
linked sugars and leaving the protein backbone. ALCAM
immunoblotting of the deglycosylated normal thyroid samples
(Fig. 6B) showed a principal band corresponding to the precursor
of 68 kDa. In contrast, in deglycosylated tumor samples, we
detected multiple bands, probably the result of a partial
deglycosylation or degradation of the putative membrane-
associated 105-kDa isoform [28] and/or a concomitant presence
of other unknown post-transduction modifications. These results
confirmed that the multiple isoforms observed in tumor samples
exhibited a prevalence associated with differential N-linked
glycosylation (Fig. 6A and B).
To assess ALCAM expression and localization in normal and
neoplastic thyroid tissues, we performed IHC analysis on formalin-
fixed and paraffin-embedded tumoral sections of four PTCs and
two MTCs. In comparison with peritumoral thyroid tissue,
ALCAM was overexpressed in all PTC and MTC tissues. With
regard to cellular localization, in MTC the surrounding non-
Figure 2. Changes in ALCAM expression induced by ionomycin
or phorbol myristate acetate (PMA). Total lysates (Lys) and
conditioned medium (CM) from TPC-1 cells, treated or not with 1 mM
ionomycin (iono) or 50 ng/mL PMA for 2 h, were resolved by 3–8% SDS-
PAGE and immunoblotted with ALCAM antibody. Both treatments led
to an increase of secreted ALCAM isoforms; especially PMA induced a
gain of 60-kDa isoform expression. Arrow indicates the membrane-
localized ALCAM isoform in lysate, and arrowheads indicate shed-
ALCAM isoforms in CM, respectively. Beta-actin was used as a loading
control.
doi:10.1371/journal.pone.0017141.g002
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showed membranous positive immunostaining, as in the sur-
rounding non-tumor tissue of PTC (Fig. 7C); while in PTC tumor
tissue ALCAM staining was localized at the membrane and in the
cytoplasm (Fig. 7D). These results are in agreement with the
annotated immunohistochemical patterns in Human Protein Atlas
database (www.proteinatlas.org).
We also used IHC to investigate the expression of CD56 and
TTF-1 in sequential sections. Intriguingly, we found that in three
out of four tested PTCs, both proteins were lost. By contrast, two
out of two tested MTCs showed positivity for CD56 and ALCAM
and negativity for TTF-1 (Table 1).
Discussion
Over the past decade, alterations in expression of ALCAM have
been reported in several human tumors and recently in renal
carcinoma and in neuroblastoma primary tumors [33]. We show
that ALCAM expression is also modulated in thyroid cancer.
Membrane-associated ALCAM isoforms were overexpressed and
highly glycosylated in tumors; in contrast, normal thyroid tissue
expressed preferentially low glycosylated ALCAM isoforms.
ALCAM was also strongly released in conditioned medium. The
proteomic characterization of ALCAM isoforms in TPC-1
cells indicated that two soluble isoforms are released into condi-
tioned medium; in addition, it suggested an unpredicted use of O-
glycosylation sites, other than the known N-glycosylation, that
could be important for both compartmentalization and secretion
[34].
IHC confirmed that ALCAM expression was higher in tumors
than in adjacent, normal peritumoral thyroid. With regard to
cellular localization, ALCAM staining was mostly located in the
cell membrane in normal thyroids and in MTCs, while in PTCs
was membrane associated and cytoplasmic. This diversity in
staining patterns could reflect tumor biology across histologies or
grading. On the basis of these data, ALCAM overexpression in
neoplastic thyroid tissues, analogously to other tumor types, could
be implicated in tumor invasiveness and dedifferentiation
processes. This concept is consistent with the loss of CD56 and
TTF-1 expression in PTCs, associated with increased tumor
invasiveness in vivo [10;35]. Multiple studies have examined
ALCAM expression at the transcript and protein levels in tumors.
There is an emerging consensus that low membrane level of
ALCAM is a bad prognostic marker in breast [24] and ovarian
cancer [20]. In this respect, the possibility that the high levels of
ALCAM expression in thyroid tumors may indicate a reprogram-
ming in transcriptional activity due the loss TTF-1 may deserve
further investigation.
Regarding medullary and papillary thyroid tumors one of the
possible mechanisms involved in ALCAM overexpression could be
Figure 3. Release of ALCAM is sensitive to ADAM17/TACE silencing. (A) Analysis of lysates from TPC-1 and A2774 cells, resolved on 4–12%
SDS-PAGE and immunoblotted with anti-ADAM17/TACE antibodies. Arrows indicate inactive (130 kDa) and active (80 kDa) forms of ADAM17/TACE
enzyme. Normalization of results was obtained with immunoblotting analysis of beta-actin. (B) Expression of ADAM17/TACE protein by TPC-1 cells
transfected with an ADAM17/TACE-specific small interfering RNA (siRNA) (OTP17), or with non-targeting siRNA (NT) as detected by western blot. The
amount of protein was calculated by comparative densitometric scanning with beta-actin. (C) ELISA detection of ALCAM release by TPC-1 cells after
transfection with siRNA specifically inhibiting ADAM-17/TACE (OTP17, black column) or with non-targeting siRNA (NT, white column). (D) Conditioned
medium (CM) from TPC-1 cells, cultured with pervanadate (PV) (60 min), epidermal growth factor (EGF) (24 h), or medium alone (ctr, 24 h) in the
presence (black columns) or in absence (white columns) of CGS27023A (CGS) was assessed by ELISA for ALCAM. Columns, means of three
experiments (cells cultured in presence of 10, 1, or 0.1 mM CGS); bars, SD. *, P,0.05. Grey bar: in absence of CGS, but in presence of orthovanadate
(OV).
doi:10.1371/journal.pone.0017141.g003
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alter ALCAM levels in TPC-1, suggesting that ALCAM
overexpression is not dependent on RET activity and that other
factors are likely to be involved (unpublished results).
Instead, we found that EGFR stimulation increases ALCAM
secretion in part through an ADAM17/TACE-dependent path-
way. We previously demonstrated the expression of EGFR in
MTC cell lines and clinical biopsies [36]. In addition, Rodriguez-
Antona et al. [37] have reported, based on a large set of MTC
cases, that EGFR is significantly overexpressed in metastases
compared with primary tumors. EGFR is also expressed in PTCs,
and EGFR signaling may represent a molecular target in poorly
differentiated thyroid carcinoma cells [38]. Our data indicate that
activated EGFR also cooperates in thyroid cancer cell lines with
the ADAM17/TACE sheddase in promoting ALCAM shedding
and soluble ALCAM release. We previously demonstrated that
ADAM17/TACE activity is involved in motility of ovarian
carcinoma cells [28].
In the present report we show that inhibition of ADAM17/
TACE function through chemical inhibitor also interfered with
TPC-1 cell migration.
This is explained by the fact that ADAM17/TACE cleavage of
transmembrane proteins such as ALCAM is an essential process
controlling many biological functions including cell adhesion and
migration. A similar anti-adhesive activity would be also expected
by antibody-mediated blockade of ALCAM adhesive functions,
which increased ovarian cancer cells motility in a previous report
[28]. However, in the case of TPC-1 cells the anti-ALCAM
antibody I/F8 failed to augment cell motility. The possible reason
of this discrepancy may depend upon the presence of several
adhesion molecules, which display redundant functions in cell-cell
adhesion and are all substrates of ADAM17/TACE. For example,
a previous report showed the expression of ICAM-1 in thyroid
carcinoma cells [39].
In parallel studies we observed that TPC-1 cells express a strong
mesenchymal phenotype, as evidenced by the expression of
mesenchymal cytoskeletal proteins, such as vimentin, and the
high deposition of extracellular matrix proteins, including
collagens and fibronectin [40]. Consistently with these observa-
tions, TPC-1 cells showed elevated levels of b1-integrin and
integrin-regulated signaling pathways, which regulate intracellular
Figure 4. CGS decreases TPC-1 cell motility. Cells were seeded onto cell culture plates, as described in materials and methods. TPC-1 cells were
exposed to CGS treatment or vehicle. At cell confluence, a scratch was performed using a 10 ml tip and the wound measured. After a 15 h treatment,
the plate area remaining free of cells was measured. The cell-free area accounted for 44.5% of the image when the scratch was applied, P,0.05 versus
DMSO control.
doi:10.1371/journal.pone.0017141.g004
Figure 5. ALCAM expression in thyroid cell lines. Analysis of TT
and MZ-CRC1 cell lysates showing ALCAM protein expression in these
thyroid cell lines. SKOV-3 and TPC-1 cell lysates were included as
controls. Total lysates from each cell line were resolved by 4–12% SDS-
PAGE and immunoblotted with anti-ALCAM antibodies. Arrow indicates
the fully glycosylated ALCAM isoform. Beta-actin was used as a loading
control.
doi:10.1371/journal.pone.0017141.g005
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PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e17141Figure 6. ALCAM expression in normal and tumor human thyroid tissue samples. (A) Total protein extracts (30 mg) from 11 papillary
thyroid carcinomas (Ca Pap), 5 medullary thyroid carcinomas (Ca Mid), and 5 normal thyroid tissues (Thyroid) were resolved by 4–12% SDS-PAGE,
transferred onto a nitrocellulose membrane, and immunoblotted with anti-ALCAM antibody. (*) indicates a non-specific background band. Beta-actin
was used as a loading control. (B) Western blot analysis of ALCAM expression of total protein extracts (30 mg) from three PTCs, two MTCs, and three
CTRLs, treated (+) or not (2) with N-glycosidase F. Beta-actin was used as a loading control.
doi:10.1371/journal.pone.0017141.g006
Figure 7. Immunohistochemical analysis of ALCAM. Membranous positive staining in surrounding non-tumor tissue (A and C) and in
medullary thyroid carcinomas (MTCs) (B). Cytoplasmic and membranous positive staining in papillary thyroid carcinomas (PTCs) (D). 1, low-power
field; 2, high-power field; N (normal tissue), T (tumor tissue).
doi:10.1371/journal.pone.0017141.g007
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cell migration [40].
Proteolysis of ALCAM in our study generated two sALCAM
fragments of different molecular weights, which seemed not
derived from differential glycosylation, as treatment with N- and
O-glycosydases still yielded two molecular forms. A possible
alternative hypothesis is that ALCAM can be cleaved at two
distinct sites: one close to the membrane and another in a more
membrane-distal region, which yield the 96-kDa and the 60-kDa
glycosylated fragments, respectively. Similarly, digestion of
immunoprecipitated ALCAM in vitro by recombinant AD-
AM17/TACE produced a fragment of about 60 kDa, suggesting
that the same enzyme may cleave ALCAM in two different sites, in
different conditions [33]. PMA stimulation of TPC-1 cells
activated ADAM17/TACE activity as detected by the increased
release of both 96 and the 60 kDa ALCAM isoforms, supporting a
role of protein kinase C (PKC) in regulating ALCAM dynamics
[41].
Future exploration of ALCAM differential function and regu-
lation in thyroid epithelium cancer and relative metastasis will
contribute to a better understanding of whether its dysregulation
contributes to disease progression and may provide insight into
whether ALCAM has active function in thyroid tumors.
Materials and Methods
Ethics Statements
This study, involving human subjects, has obtained ethics
approval from Independent Ethics Committee (IEC) of Fonda-
zione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Reagents, cell culture media, antibodies, and enzymes
Sodium orthovanadate (Na3VO4), PMA, ionomycin, PMSF,
and DMSO were supplied from Sigma-Aldrich (Milan, Italy);
protease inhibitor cocktail tablets (Complete Mini) from Roche
(Milan, Italy); and Bradford reagent from BioRad (Milan, Italy).
DMEM was from Gibco (Invitrogen; Milan, Italy); FBS and FCS
from HyClone (Celbio; Milan, Italy); RPMI 1640, Ham’s F12,
sodium pyruvate, L-glutamine, and trypsin-EDTA solution from
BioWhittaker (Lonza; Milan, Italy); and HEPES buffer from
EuroClone (Celbio; Milan, Italy). Anti-ALCAM antibody was
from Novocastra (Leica; Milan, Italy); anti–b-actin and anti-
ADAM17/TACE antibodies were respectively from Sigma-
Aldrich and AbCam (Cambridge, MA, USA). I/F8 scFv antibody
is described in [42]. Anti–TTF-1 antibody was from Novus
Biological (DBA, Milan, Italy). Anti-rabbit IgG, horseradish
peroxidase–linked whole antibody (from donkey), anti-mouse
IgG, and horseradish peroxidase–linked whole antibody (from
sheep) were supplied from GE Healthcare (Milan, Italy); and anti-
goat antiserum was from ZYMED Laboratories (Invitrogen;
Milan, Italy). N-glycosidase F (PNGaseF) was purchased from
New England Biolabs (Celbio; Milan, Italy) and O-glycosidase and
a(2
R3,6,8,9)neuraminidase (sialidase) from Sigma-Aldrich.
Tissue samples and protein extraction
MTC and PTC specimens and normal thyroid tissues were
obtained from 22 patients, who provided written informed consent
to participate in the study according to the ethical guidelines of our
Institute, after surgery. Tissue samples were pulverized and
processed as described in [36].
Preparation of cell lysates
Cells were lysed and processed as described in [36].
Cell cultures
Cell lines were grown as follows: human PTC cell line TPC-1 in
DMEM, supplemented with 10% FBS; human MTC cell line TT
in Ham’s F12, supplemented with 15% FCS; human MTC cell
line MZ-CRC1 in DMEM, supplemented with 10% FCS; human
ovarian cancer cell line A2774 [28] and human ovarian cancer cell
line SKOV-3 (from American Type Culture Collection; Milan,
Italy) in RPMI 1640, supplemented with 10% FCS.
Preparation of conditioned media
TPC-1 cells were seeded at 3610
4 cells/cm
2 and cultured for
4 d. Medium was removed, and cells were washed four times with
PBS and once with serum-free medium. Serum-free DMEM was
added and plates incubated for 24 h. The CM was collected,
centrifuged at 4000 rpm for 10 min to remove cell debris, and
finally concentrated and desalted using a spin column (Agilent
Technologies; Milan, Italy).
N-deglycosylation and O-deglycosylation reactions
Cell lysates and CM proteins were O-deglycosylated with a
mixture of O-glycosidase and a(2R3,6,8,9) neuraminidase
(sialidase), with or without PNGaseF. A total of 100 mg of protein
from each sample was treated with 5 mU of O-glycosidase and
Table 1. Immunohistochemical reactivity of thyroid tumors.
Case n. ALCAM TTF-1 CD56 Carcinoma diagnosis
Cytoplasmic
staining
Membranous
staining
Nuclear
staining
Membranous
staining
1- + - + MTC
2- + - + MTC
3 +++ +PTC
4 ++-- P T C
5 ++-- P T C
6 ++-- P T C
ALCAM, activated leukocyte cell adhesion molecule; PTC, papillary thyroid carcinoma;
MTC, medullary thyroid carcinoma.
CD56 and TTF-1 were negative in three out of four PTC cases. MTCs showed comparable positive immunostaining results for CD56 but were completely negative for
TTF-1.
doi:10.1371/journal.pone.0017141.t001
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performed, using 1 U/100 mg of protein.
SDS-PAGE and western blotting
The procedures were performed as previously described in [36].
Drug treatments
To test effects of ionomycin or PMA on ALCAM secretion
and shedding, TPC-1 cells were seeded at 3610
4 cells/cm
2, grown
for 3 d, and then treated with 1 mM or 50 ng/mL for 2 h,
respectively.
ADAM17/TACE inhibition and ELISA assay
ADAM 17/TACEwasinhibitedwithmetalloproteinase inhibitor
CGS27023A (CGS) as previously described [28] Conditioned
media from TPC-1 and A2774 cells treated with PV, EGF, or
medium alone with or without CGS were then collected,
centrifuged at 1000 rpm, and used undiluted for secreted ALCAM
detection with the DuoSet ELISA Development Kit (R&D Systems;
Milan, Italy) based on the anti-human ALCAM mAB Clone
105902 as capturer and on a biotinylated polyclonal goat anti-
human ALCAM serum as the detection antibody. Assays were done
in triplicate, and background values were subtracted. Data were
expressed as the mean 6 SD and analyzed using a two-tailed
Student’s t test or the Mann-Whitney test.
Small interfering RNA (siRNA) transfection
TPC-1 cells were transfected with the ON-TARGET plus
SMART pool for human ADAM17/TACE or siCONTROL
Non-Targeting siRNA pool (Dharmacon; Milan, Italy), using
Lipofectamine RNAiMAX (Invitrogen). Transfected cultures were
assayed for constitutive or induced ALCAM shedding 48 h after
siRNA delivery. Cells were harvested by PBS-EDTA treatment
and processed for RNA and protein extraction to detect
ADAM17/TACE mRNA and protein.
Scratch assay
The assay was made as previously described [28] and visualized
by comparing photographs taken at the time of addition of EGF
and 15 h later, by a Nikon DS-5M Camera System mounted on a
phase-contrast Leitz microscope. The distance traveled by the cells
was determined by measuring the cell-free area width at time 15 h
and subtracting it from the cell-free area width at time 0. The
values obtained were then expressed as % migration, setting the
gap width at t0 as 100%. Two experiments were done in triplicates.
Immunohistochemistry (IHC)
The IHC analyses were made using 2 mm of the formalin-fixed
and paraffin-embedded tumoral sections with antibodies against
ALCAM and CD56 as described in Mezzanzanica et al. [20] and
in Scarpino et al., [10] respectively. All of the samples were also
immunophenotyped using an anti–TTF-1 antibody (diluted 1:75),
and the antigens were retrieved using 10 mM citrate buffer
(pH 6.0) in an autoclave at 95uC for 15 min.
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